COVID-19 symptoms and duration of direct antigen test positivity at a 1 community testing and surveillance site, January 2021-2022 2 3 Short title: COVID-19 symptoms and rapid antigen test positivity at a community 4 testing site. 5 **AUTHORS:** Carina Marguez MD¹, ^{*}Andrew D. Kerkhoff MD, PhD¹, John Schrom, MPH¹, 6 Susana Rojas², Douglas Black BA¹, Anthea Mitchell, BA³, Chung-Yu Wang, BA³, 7 Genay Pilarowski PhD⁴, Salustiano Ribeiro MS⁵, Diane Jones RN⁴, Joselin Payan⁴, 8 Simone Manganelli MS⁴, Susy Rojas BS⁴, Jonathan Lemus BA⁴, Vivek Jain¹ MD, 9 Gabriel Chamie MD¹, Valerie Tulier-Laiwa JD², Maya Petersen MD, PhD⁶, Joseph 10 DeRisi PhD³**. Diane V. Havlir MD^{1**} 11

12

13 Affiliations:

- ¹⁴ ¹Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San
- 15 Francisco General Hospital, University of California San Francisco
- ²The San Francisco Latino Task Force-Response to COVID-19, San Francisco, CA,
 USA
- ¹⁸ ³Chan-Zuckerberg Biohub, San Francisco, CA
- ⁴Unidos en Salud, San Francisco, CA, USA
- ⁵Bay Area Phlebotomy and Laboratory Services, San Francisco, CA, USA
- ⁵Division of Biostatistics, School of Public Health, University of California, Berkeley,

22 Berkeley, CA, USA

- 23
- 24 **Authors contributed equally
- 25
- 26 **Corresponding author:**
- 27 *Carina Marquez, MD, MPH
- 28 Associate Professor of Medicine
- 29 Division of HIV, Infectious Diseases Global Medicine
- 30 University of California, San Francisco
- 31 Zuckerberg San Francisco General Hospital
- 32 995 Potrero Ave
- 33 San Francisco, CA 94110
- 34 carina.marquez@ucsf.edu
- 35 Phone: 415-476-4082
- 36 Fax: 415-476-6953
- 37

- 39 Manuscript Word count: 2983
- 40 **Keywords:** COVID-19; Omicron; rapid antigen testing

- 42
- 43
- 44
- 45
- 46

48

49 Abstract

- 50
- 51 **Importance:** Characterizing clinical symptoms and evolution of community- based
- 52 SARS Co-V-2 infections can inform health practitioners and public health officials in a
- 53 rapidly changing landscape of population immunity and viral variants.
- 54 **Objective**: To characterize COVID-19 symptoms during the Omicron period compared
- 55 to pre-Delta and Delta variant periods and assess the duration of COVID-19 BinaxNOW
- 56 rapid antigen test positivity during the Omicron variant surge.
- 57 Design, Setting, and Participants: This public health surveillance study was
- undertaken between January 2021- January 2022, at a walk-up community COVID-19
- 59 testing site in San Francisco, California. Testing with BinaxNOW rapid antigen tests was
- 60 available regardless of age, vaccine status, or symptoms throughout.
- 61 Main Outcomes and Measures: We characterized the prevalence of specific
- 62 symptoms for people with a positive BinaxNOW test during the Omicron period and
- 63 compared it to the pre-Delta and Delta periods. During the Omicron period, we
- 64 examined differences in symptoms by age and vaccine status. Among people returning
- 65 for repeat testing during Omicron period, we estimated the proportion with a positive
- 66 BinaxNOW antigen test between 4-14 days from symptom onset or since first positive
- 67 test if asymptomatic.
- 68 **Results:** Of 63,277 persons tested, 18,301 (30%) reported symptoms and 4,568 (25%)
- 69 tested positive for COVID-19. During the Omicron period, 41.6% (3032/7283) of
- symptomatic testers tested positive, and the proportion reporting cough (67.4%) and

71	sore throat (43.4%) was higher than during Delta and pre-Delta periods. Congestion
72	was higher during Omicron (38.8%) than during the pre-Delta period and loss of
73	taste/smell (5.3%) and fever (30.4%) were less common. Fevers and myalgias were
74	less common among persons who had received boosters compared to unvaccinated
75	people or those who received the primary series. Five days after symptom onset, 31.1%
76	of people with COVID-19 stated their symptoms were similar or worsening. An
77	estimated 80.2% of symptomatic re-testers remained positive five days after symptom
78	onset and 60.5% after ten days.
79	Conclusions and Relevance: COVID-19 upper respiratory tract symptoms were more
80	commonly reported during the Omicron period compared to pre-Delta and Delta
81	periods, with differences by vaccination status. Antigen test positivity remained high
82	after 5 days, supporting guidelines requiring a negative test to shorten the isolation
83	period.
84	
85	
86	
87	
88	
89	

92 Key points

- **Question:** During the Omicron period, are there differences in COVID-19
- 94 symptomatology compared to the pre-Delta and Delta periods and how long do rapid
- 95 antigen tests remain positive?

96	Findings: In this community-based surveillance study we detected differences in
97	symptomatology between the Omicron period and prior variant-periods, and by age and
98	vaccination status. Five days after symptom onset, 80% remained positive with a
99	BinaxNOW test.
100	Meaning: During the Omicron period, differences in symptomatology may be due to
101	rising population immunity and a new variant. BinaxNOW positivity remained high
102	among re-testers, which supports guidelines that use rapid tests to shorten the isolation
103	period.
104	
105	
106	
107	
108	

111 Introduction

112 COVID-19 symptoms are an important entry point into testing, treatment, and 113 isolation. Prompt entry into this sequence of care is critical to breaking chains of transmission and starting anti-viral treatment early in infection^{1,2}. As population immunity 114 115 and viral variants evolve in the ongoing SARS CoV-2 pandemic, understanding 116 symptomatology, symptom duration, and the use of changing diagnostic modalities, 117 such as rapid antigen tests, can help inform medical providers and public health leaders 118 on clinical management and key policy questions. National studies from the United 119 Kingdom (UK) have demonstrated changes in COVID-19 symptom profile by viral variant.^{3–5} However, there has not been a large study of symptom variation by variant 120 121 wave among outpatients outside of the UK. Further, there have been relatively few data 122 during the Omicron surge on COVID-19 symptoms, their duration, variation in adult and 123 pediatric populations, and variation by vaccination status.

124 Understanding the duration of symptoms and infectiousness can inform many policy questions, including return to work guidelines, and individual decisions during 125 126 COVID-19 surges. Although the US Centers for Disease Control (CDC) recommended return to work after 5 days if symptoms improve⁶, a recent study from Alaska and two 127 128 studies of health care workers showed that over 50-80% of people remain rapid antigen 129 test positive 5 days after symptom onset. These data raise concerns about persistent 130 infectiousness after 5 days, as antigen test positivity strongly correlates with the presence of viable virus.^{7–11} 131

132 Among persons testing at a walk-up COVID-19 testing site in San Francisco that serves Latinx residents¹² – a community disproportionately affected by COVID-19¹² – 133 our objective was to first determine the prevalence and characteristics of specific 134 135 symptoms among symptomatic COVID-19 positive persons during the Omicron period 136 compared to the Delta and pre-Delta periods as population immunity and variants 137 evolved. During the Omicron period we further sought to assess how symptoms varied 138 by vaccination status and age and to characterize symptom duration and persistence of 139 a positive BinaxNOW rapid antigen test.

140

141 Methods

142 Study setting and participants

143 This public health surveillance study was undertaken between January 10, 2021, and 144 January 31, 2022 at the Unidos en Salud (UeS) neighborhood testing and vaccine site, 145 which is located in the Mission District of San Francisco. The UeS neighborhood testing 146 and vaccination site was co-designed through a community-academic partnership 147 between the San Francisco Latino Task Force- Response to COVID-19 (LTF), University of California, San Francisco (UCSF), and the Chan Zuckerberg Biohub.^{2,13} 148 149 The site serves predominantly low-income Latinx persons, a large majority of whom are low-wage earning frontline and essential workers.¹ It is conveniently located near a busy 150 151 transportation hub and offers free walk-up testing with no request for residency or health 152 insurance information. Throughout the study period, we conducted community outreach 153 consistently, messaging the importance of regular testing regardless of symptoms and

vaccination status due to the elevated risk of acquiring COVID-19 among the populationserved by the site.

156

157 Ethics statement

158 The study was conducted under a public health surveillance program that was reviewed

159 by the UCSF Committee on Human Research and determined to be exempt and waived

160 from IRB oversight. All participants provided informed consent in their preferred

161 language prior to survey administration and COVID-19 testing.

162

163 **Procedures and samples**

164 All participants or their caretakers completed a structured electronic survey capturing 165 socio-demographics, vaccination status, symptoms (including date-of-onset and 166 trajectory [e.g., improving, unchanged, worsening]). Trained laboratory assistants 167 performed a bilateral anterior nasal swab for COVID-19 testing using the BinaxNOW COVID-19 Ag Card (Abbott Diagnostics) and a bilateral nasal swab for sequencing. ^{14,15} 168 We performed genotyping of all isolates as previously described.¹⁶ Full genome 169 170 sequences are available through GISAID and previously described for the pre-Delta period (majority being Epsilon¹⁷ and Alpha variants) and for the Omicron period.¹⁶ 171 172 During the Omicron period, community health workers reminded people testing positive 173 to repeat their test 5 days after symptom onset or their initial test to assess candidacy for shortening isolation per California Department of Public Health guidelines.¹⁸ Clients 174 175 received a text message reminding them of this option.

176

177 **Definitions and Statistical Analysis**

178 For analysis purposes, three time periods were defined, corresponding to distinct 179 COVID-19 waves: (1) Pre-Delta period: January 10, 2021 to May 31, 2021; (2) Delta 180 period: June 1, 2021 to November 30, 2021; and, (3) Omicron period: December 1, 181 2021 to January 30, 2022. Two different analysis populations were defined. 182 First, among symptomatic testers (n=18,301) we calculated the proportion with a 183 positive BinaxNOW rapid antigen test and the prevalence of specific symptoms during 184 each variant period (Omicron, Delta, and pre-Delta), stratified by rapid antigen test 185 result. Among persons with a positive rapid antigen test we evaluated whether symptom 186 prevalence differed between the Omicron compared to the Delta and pre-Delta periods. 187 Finally, during the Omicron period, we also assessed symptom prevalence by age and

188 vaccination status, and determined whether self-reported symptoms improved,

189 worsened, or remained unchanged over days following the test.

190 The second analysis (n=942) sought to understand the proportion of participants 191 during the Omicron wave with a positive repeat COVID-19 BinaxNOW rapid antigen test 192 result. This analysis was restricted to 're-testers', defined as participants who had a 193 positive BinaxNOW rapid antigen test result on or after January 1, 2022, and had at 194 least one additional BinaxNOW rapid antigen result two or more days after their initial 195 positive test. For each day from 4 to 14 following symptom onset, or day since initial 196 positive test if asymptomatic, we estimated the proportion of persons who remained 197 positive by day. Participants whose second test was positive were assumed to be 198 positive each day between the positive tests. Test positivity on days between a positive 199 and a negative test was imputed in three different ways: (1) assuming a linearly

decreasing probability of testing positive between their two tests (main analysis), (2) assuming that tests would have converted to negative the day after their initial positive test (lower bound of sensitivity analysis), (3) assuming that tests would have remained positive until the day before their repeat negative test (upper bound of sensitivity analysis). We further stratified analyses test by symptom and vaccine status. For completeness, we also report positivity over time among repeat testers without imputation of results between tests.

For both analysis populations, Fisher's exact or chi-squared tests were used as appropriate to compare proportions. Kruskal-Wallis tests were used to compare medians. We report both unadjusted p-values and, for multiple comparisons of symptom prevalence across periods, vaccination, and age strata, p-values adjusted using the Benjamin-Hochberg method to control false discovery rate at 5%.

212

213 **Results**

214 Between January 10, 2021, and January 31, 2022, 63,277 persons underwent COVID-215 19 testing at the UeS Neighborhood site. Overall, 18,301 (29.9%) participants across all 216 waves reported at least one current symptom at the time of COVID-19 testing; 37.1% 217 (n=7,823) during Omicron, 28.3% during Delta (n=5,485), and 22.8% (n=5,533) during 218 the pre-Delta period. Test positivity was 41.6%, 8.5%, and 19.2%, respectively. Overall, 219 the median age of testers was 32 (IQR: 21-44) years old, 12.0% were <12, 52.0% were 220 women, and 68.5% were Latinx. During the Omicron period, the median age was 34.2, 221 52.6% were female, 74.3% were Latinx, 73.0% of reported a household income of 222 <\$50,000 per year. We detected small differences in who sought testing by variantperiod according to age, gender, and race (Supplementary Table 1). The proportion of
unvaccinated participants increased throughout variant periods, during Omicron 12.7%
of symptomatic testers were unvaccinated compared to 39.7% during the Delta period,
and 93.3% during the pre-Delta period, p<0.01 (Supplementary Table 1).

227

228 Symptom Profile of People Testing Positive for COVID-19

229 During the Omicron period (n=3,032), the most common symptoms reported by 230 persons testing positive for COVID-19 by BinaxNOW rapid antigen tests were cough 231 (67.4%), sore throat (43.4%), congestion (38.8%), headache (35.5%), while loss of 232 smell/taste (5.3%), nausea (5.0%) and diarrhea (4.8%) were the least commonly 233 reported (Table 1A). The proportion of symptomatic COVID-19 positive persons 234 reporting cough and sore throat was higher during the Omicron period relative to Delta 235 and pre-Delta periods, while fever, and loss of taste/smell decreased relative to Delta 236 and pre-Delta periods (Table 1A, Supplementary Figure 1, p<0.05 for all comparisons). 237 Congestion was more common among symptomatic people testing positive during the 238 Omicron period compared to pre-Delta (p<0.001). The leading COVID-19 symptoms 239 among symptomatic people testing positive during the Omicron period (cough, sore 240 throat, and congestion) were also common among symptomatic people who tested 241 negative (Table 1, Supplementary Figure 1). 242 During the Omicron period, 47.7% of symptomatic children (<12 years) with 243 COVID-19 reported only one symptom. Reporting a single symptom was less common

among adults (37.7%, p<0.001) and adolescents (31.8%, p<0.001) (Supplemental

Table 2). Among children with COVID-19, cough, fever, sore throat, and congestion

were the most common symptoms. Loss of taste/smell was uncommon among children
(0.3%) compared to adolescents (5.8%, p<0.001) and adults (5.8%, p<0.001) (Table
1B).

We also found differences in symptoms according to vaccination status (Table 3). Among boosted persons, congestion was more common, and fever was less common compared to both unvaccinated people and vaccinated/non-boosted people (p<0.05 for all comparisons; Table 1C); myalgias were also less common among boosted persons compared to vaccinated/non-boosted persons (p=0.01). The prevalence of other symptoms did not differ by vaccination status.

255

Time to improvement of COVID-19 symptoms during the Omicron period

257 Next, we evaluated the trajectory of symptoms among persons testing COVID-19

positive during the Omicron period (**Figure 1A**; n=1,613). Among participants tested five

days after symptom onset, 63.0% (95%CI: 56.6-69.2) of persons had improving

symptoms by day of testing, symptoms were similar in 31.1% (95%CI: 25.3%-37.4%)

and in 5.9% were worsening (95%CI: 3.3%-9.7%). Among participants testing ten days

after symptom onset, symptoms were improving in 82.2% (95%CI: 56.6%-69.2%), were

similar in 17.8% (95%CI: 9.8%-28.5%) and were worsening in 0% (95%CI: 0%-4.9%).

Symptom trajectory was similar across vaccination status or age (**Figure 1B, 1C**).

265

266 COVID-19 repeat testing results

Among persons who undertook COVID-19 re-testing, an estimated 65% (95%CI: 62%-

268 69%) people remained test-positive 5 days after symptom onset or 5 days from their

269 initial positive test if they were asymptomatic (Figure 2A). Among symptomatic persons, 270 an estimated 80% (95% CI: 76%-84%) and 35% (95% CI: 30%-40%) remained positive 271 on day 5 and 10 respectively. Among persons asymptomatic at testing, an estimated 272 49% (95% CI: 34-55%) and 19% (95% CI, 5%-42%) remained positive on day 5 and 10. 273 Repeat test positivity was higher among symptomatic vs. asymptomatic testers on day 5 274 and 10. (Figure 2B). We found no difference in trajectory of test positivity over time by 275 vaccination status (Figure 2C). Similar results were found using non-imputed values for 276 interim test positivity (Supplementary Figure 2A-2C).

277

278 **Discussion**

279 Over the course of three different COVID-19 surges, each with a different 280 predominant SARS-CoV-2 variant, and against a backdrop of rising population 281 immunity, we found a shift towards predominantly upper respiratory tract symptoms with 282 the Omicron variant among symptomatic persons presenting for COVID testing at a low-283 barrier, walk-up testing site. Omicron symptom trajectories were heterogenous, with a 284 third of people reporting no improvement or worsening of symptoms when they returned 285 for repeat testing with a BinaxNOW rapid antigen test after 5 days. During the Omicron 286 surge, 80% of symptomatic persons with COVID-19 returning for repeat testing were 287 BinaxNOW positive after 5 days, and 35% still positive after 10 days, regardless of 288 vaccine status. These results provide updated clinical data on COVID-19 outpatients 289 and rapid antigen test positivity to guide safe return-to-work guidelines.

290 In over 3,000 symptomatic people testing positive for COVID-19 during an 291 Omicron surge, upper respiratory tract symptoms (sore throat, congestion) were more 292 common than during pre-Delta and Delta periods. The loss of taste and smell - often 293 used by clinicians to help distinguish SARS Co-V 2 from other viral illness - was much 294 less common during the Omicron period (5.3%) compared to the pre-Delta (17.2%) and 295 Delta (20.5%) periods. This shift in symptomatology seen from pre-Delta to Omicron is 296 likely due to both the increase in population immunity during the Omicron surge and 297 biologic characteristics of the Omicron variant, which in vitro-studies suggest replicates better in bronchial tissue versus deeper lung sites.¹⁹ During the Omicron surge, 298 299 symptoms also varied by vaccine status; congestion was more common, and fever and 300 myalgia were less common among boosted persons compared to partially or 301 unvaccinated persons.

302 Our findings are concordant with a population-representative household study conducted during the Omicron period in the United Kingdom (UK)⁵ that found a 303 304 predominance of upper respiratory tract symptoms. Additionally, our data expands 305 existing knowledge on COVID-19 symptomatology by describing differences in 306 symptomatology by vaccine status and age-group. Assessing the ability of symptoms to 307 predict test positivity was outside the scope of our analysis. However, similar to findings from the UK findings,⁵ we found the background rate of common COVID-19 symptoms 308 309 during the Omicron period to be high among both people who tested both positive and 310 negative. These findings emphasizing the importance of ensuring low-barrier testing is 311 available regardless of the tester's symptom profile.

312 This study is one of the few in the Omicron era to describe symptoms of mild-313 moderate infection in children. While symptoms were heterogenous in children, over 314 40% of children under the age of 12 had only one symptom, with fever, cough, and 315 congestion being the most common. It is important to recognize that children, especially 316 those under five, may present with only one symptom. Thus, parents and health care 317 providers should have a low-threshold to test children with any symptom potentially 318 concerning for COVID-19. Rapid and easily accessible testing is an important strategy to keep children in school, while minimizing transmission.^{21,22} 319

320 Despite lower frequencies of constitutional symptoms during the Omicron surge, 321 it is noteworthy that recovery varied and 31% of patients did not report perceived 322 improvement by day 5. During the Omicron surge, frontline workers were urged to 323 return to work to meet staffing needs in occupations such as transport, home health 324 care, and the food service industry. During surges of the magnitude of Omicron, 325 frontline workers can be urged to return to work to meet staffing needs in occupations 326 such as transport, home health care, and the food service industry. Despite not having 327 illness serious enough to merit hospitalization, many persons with Omicron still felt ill, 328 yet felt pressure by their employers to return to work. Safeguards routinely in place in the formal sector in the United States, are often unavailable in the informal sector.^{23,24} 329 330 Pandemic planning must account for these health and economic pressures in future 331 surges.

332 Of persons with COVID-19 re-testing on Day 5, 80% of symptomatic people and 333 41% of asymptomatic people remained positive. This number is nearly identical to a 334 community-based sample of people seeking testing in Alaska²⁵ and similar to the

findings in two cohorts of health care workers^{26,27}. This high proportion of positive repeat 335 336 tests is not surprising, given existing data on viral dynamics of Omicron and other 337 variants. In a predominantly boosted cohort from the National Basketball Association 338 (NBA), viral trajectories of Omicron were heterogenous, but the duration of the acute 339 phase (proliferation and clearance) was 9.9 days and similar to prior variants, including Delta.^{28,29} Additionally, in this cohort of predominantly healthy, boosted NBA players 340 341 with infections due to the Omicron variant, only 52% of people had a cycle threshold of <30 5 days after symptom onset.²⁸ 342

Interestingly, we found that COVID-19 test positivity remained high even 10 days following symptom onset, where more than 30% or people with symptomatic COVID-19 during their initial still had a positive rapid antigen test. Additional epidemiologic studies are needed to assess whether people remain infectious at this juncture. However, prior studies show a strong correlation between rapid antigen positivity and viable virus,^{7–9,30} even in the clearance phase and after 10 days of symptom onset ^{9,10,31}- suggesting infectiousness beyond 10 days may be possible, though less common.

Positive rapid antigen tests correlate to having viable virus, and thus capture persons with the highest degree of infectivity to others.^{7–9,11} The CDC recommends that people can leave isolation with a well-fitting mask after 5 days of symptoms if symptoms are improving, regardless of repeat testing.⁶ If a public health goal is to break chains of SARS CoV-2 transmission, our data strongly support current California Department of Public Health guidelines¹⁸ that require a rapid antigen test to shorten the 10-day isolation period.

Strengths of our study include the use of data spanning multiple COVID-19 357 358 pandemic waves from one high-throughput, low-barrier, community-based testing site 359 that predominantly serves a highly impacted low-income Latinx population. Further, 360 symptom ascertainment and testing procedures did not change during the surveillance 361 period. Our study had certain limitations. Although it was cross-sectional, our data 362 provide an important synthesis of symptomatology within a diverse population of people 363 seeking community testing. Second, symptoms and timing of onset were self-reported 364 which, may introduce bias; however, symptom data were collected prior to persons 365 knowing their COVID-19 test result and thus would not be expected to result in 366 differential bias between those who were COVID-19 positive and negative. Additionally, 367 we did not characterize the severity of COVID-19 symptoms across waves, and even a 368 single very severe symptom can cause substantially greater morbidity in an individual 369 than multiple mild symptoms. Finally, testing was undertaken with rapid antigen tests, 370 and thus may have resulted in misclassification of individuals during the earliest phases 371 of their illness. Nonetheless, strict quality control measures were implemented to ensure 372 accuracy of results and the use of rapid antigen tests.

In summary, the clinical presentation of symptomatic persons changed over time during several COVID surges characterized by increasing population immunity and different SARS CoV-2 variants. During Omicron, when population immunity was higher, persons with symptoms often did not see improvement after 5 days and antigen tests frequently remained positive. These findings highlight the importance of work assurances to protect workers and requirements for rapid antigen testing to shorten isolation to protect the workplace. With the dynamic landscape of host immunity and

viral evolution, we need real time data from diverse populations for clinicians, public health officials and the community to develop optimal strategies to mitigate the health, economic and societal effects for SARS CoV-2 and to ensure that inequities in this disease are not exacerbated. Funding/Support: This program was supported by the University of California San Francisco, John P. McGovern Foundation, and the Chan Zuckerberg Health Initiative. The BinaxNOW cards were provided by the California Department of Public Health. Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

404		
405		
406		
407		
408		
409		
410	Re	ferences
411		
412	1.	Rubio LA, Peng J, Rojas S, et al. The COVID-19 Symptom to Isolation Cascade in
413		a Latinx Community: A Call to Action. Open Forum Infect Dis. 2021;8(2):ofab023.
414		doi:10.1093/ofid/ofab023
415	2.	Pilarowski G, Marquez C, Rubio L, et al. Field Performance and Public Health
416		Response Using the BinaxNOWTM Rapid Severe Acute Respiratory Syndrome
417		Coronavirus 2 (SARS-CoV-2) Antigen Detection Assay During Community-Based
418		Testing. Clin Infect Dis. 2021;73(9):e3098-e3101. doi:10.1093/cid/ciaa1890
419	3.	Elliott J, Whitaker M, Bodinier B, et al. Predictive symptoms for COVID-19 in the
420		community: REACT-1 study of over 1 million people. PLOS Medicine.
421		2021;18(9):e1003777. doi:10.1371/journal.pmed.1003777
422	4.	Vihta KD, Pouwels KB, Peto T, et al. Symptoms and SARS-CoV-2 positivity in the
423		general population in the UK. Clin Infect Dis. Published online November 8,
424		2021:ciab945. doi:10.1093/cid/ciab945

- 425 5. Vihta KD, Pouwels KB, Peto TE, et al. Omicron-Associated Changes in Sars-Cov-2
 426 Symptoms in the United Kingdom. Published online January 18,
- 427 2022:2022.01.18.22269082. doi:10.1101/2022.01.18.22269082
- 428 6. CDC, CDC. Quarantine & Isolation. Centers for Disease Control and Prevention.
- 429 Published January 27, 2022. Accessed March 6, 2022.
- 430 https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html
- 431 7. Currie DW, Shah MM, Salvatore PP, et al. Relationship of SARS-CoV-2 Antigen
- 432 and Reverse Transcription PCR Positivity for Viral Cultures. *Emerg Infect Dis.*
- 433 2022;28(3):717-720. doi:10.3201/eid2803.211747
- 434 8. Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic
- 435 performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in
- 436 monitoring the infectiousness of COVID-19 patients. *Sci Rep.* 2021;11(1):22863.
- 437 doi:10.1038/s41598-021-02197-z
- 438 9. Killingley B, Mann A, Kalinova M, et al. Safety, tolerability and viral kinetics during
- 439 SARS-CoV-2 human challenge | Research Square. *Research Square*. Accessed
- 440 March 6, 2022. https://www.researchsquare.com/article/rs-1121993/v1
- 10. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and
- 442 correlation with RT-PCR cycle threshold values in cases of COVID-19, England,
- 443 January to May 2020. *Eurosurveillance*. 2020;25(32). doi:10.2807/1560-
- 444 **7917.ES.2020.25.32.2001483**

445	11.	Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout
446		SARS-CoV-2 infection course. Science. 2021;373(6551):eabi5273.
447		doi:10.1126/science.abi5273
448	12.	Chamie G, Marquez C, Crawford E, et al. SARS-CoV-2 Community Transmission
449		disproportionately affects Latinx population during Shelter-in-Place in San
450		Francisco. Clin Infect Dis. Published online August 21, 2020.
451		doi:10.1093/cid/ciaa1234
452	13.	Marquez C, Kerkhoff AD, Naso J, et al. A multi-component, community-based
453		strategy to facilitate COVID-19 vaccine uptake among Latinx populations: From
454		theory to practice. PLoS One. 2021;16(9):e0257111.
455		doi:10.1371/journal.pone.0257111
456	14.	Abbott Diagnostics. Abbott BinaxNOW COVID-19 Ag Package Insert, version 1.6.
457		Accessed October 20, 2020. https://www.fda.gov/media/141570/download
458	15.	Unidos en Salud. Binax Training Resources. United In Health. Accessed December
459		17, 2020. https://unitedinhealth.org/binax-training
460	16.	Schrom J, Marquez C, Pilarowski G, et al. Direct Comparison of SARS-CoV-2
461		Nasal RT-PCR and Rapid Antigen Test (BinaxNOW TM) at a Community Testing
462		Site During an Omicron Surge. medRxiv. Published online January 19,
463		2022:2022.01.08.22268954. doi:10.1101/2022.01.08.22268954
464	17.	Peng J, Liu J, Mann SA, et al. Estimation of Secondary Household Attack Rates for

465 Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2

	(SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based
	Testing Site in San Francisco. Clin Infect Dis. 2022;74(1):32-39.
	doi:10.1093/cid/ciab283
18.	Guidance on Isolation and Quarantine for COVID-19 Contact Tracing. Accessed
	March 6, 2022. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-
	19/Guidance-on-Isolation-and-Quarantine-for-COVID-19-Contact-Tracing.aspx
19.	Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in
	human bronchus and lung ex vivo. Nature. Published online February 1, 2022.
	doi:10.1038/s41586-022-04479-6
20.	Antonelli M, Capdevila J, Chaudhari A, et al. Optimal symptom combinations to aid
	COVID-19 case identification: Analysis from a community-based, prospective,
	observational cohort. Journal of Infection. 2021;82(3):384-390.
	doi:10.1016/j.jinf.2021.02.015
21.	Lanier WA. COVID-19 Testing to Sustain In-Person Instruction and Extracurricular
	Activities in High Schools — Utah, November 2020–March 2021. MMWR Morb
	Mortal Wkly Rep. 2021;70. doi:10.15585/mmwr.mm7021e2
22.	Bilinski A, Ciaranello A, Fitzpatrick MC, et al. SARS-CoV-2 testing strategies to
·	contain school-associated transmission: model-based analysis of impact and cost
	of diagnostic testing, screening, and surveillance. medRxiv. Published online
	19. 20. 21.

485 August 10, 2021:2021.05.12.21257131. doi:10.1101/2021.05.12.21257131

486	23.	Macias Gil R, Marcelin JR, Zuniga-Blanco B, Marquez C, Mathew T, Piggott DA.
487		COVID-19 Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in
488		the United States. J Infect Dis. Published online July 30, 2020.
489		doi:10.1093/infdis/jiaa474
400	0.4	
490	24.	US Bureau of Labor Statistics. 2019 National Compensation Survey.; 2019.
491		https://www.bls.gov/ncs/ebs/
492	25.	Lefferts B. Antigen Test Positivity After COVID-19 Isolation — Yukon-Kuskokwim
493		Delta Region, Alaska, January–February 2022. MMWR Morb Mortal Wkly Rep.
494		2022;71. doi:10.15585/mmwr.mm7108a3

- 495 26. Landon E, Bartlett AH, Marrs R, Guenette C, Weber SG, Mina MJ. High Rates of
- 496 Rapid Antigen Test Positivity After 5 days of Isolation for COVID-19. *medRxiv*.

497 Published online February 2, 2022:2022.02.01.22269931.

- 498 doi:10.1101/2022.02.01.22269931
- 499 27. Stiefel U, Bhullar D, Zabarsky TF, et al. Healthcare personnel frequently have
- 500 positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen
- 501 tests 5 days or more after diagnosis of coronavirus disease 2019 (COVID-19).
- 502 *Infect Control Hosp Epidemiol.* Published online February 8, 2022:1-2.
- 503 doi:10.1017/ice.2022.21
- 504 28. Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity
- 505 of the SARS-CoV-2 Omicron variant. *medRxiv*. Published online January 14,
- 506 2022:2022.01.13.22269257. doi:10.1101/2022.01.13.22269257

507	29.	Kissler SM, Fauver JR, Mack C, et al. Viral Dynamics of SARS-CoV-2 Variants in
508		Vaccinated and Unvaccinated Persons. New England Journal of Medicine.
509		2021;385(26):2489-2491. doi:10.1056/NEJMc2102507
510	30.	Korenkov M, Poopalasingam N, Madler M, et al. Evaluation of a Rapid Antigen Test
511		To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals. J
512		Clin Microbiol. 2021;59(9):e0089621. doi:10.1128/JCM.00896-21
513	31.	Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and
514		vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv.
515		Published online January 18, 2022:2022.01.10.22269010.
516		doi:10.1101/2022.01.10.22269010
517		
518		
519		
520		
521		
522		
523		
524		
525		
526		
527		
528		
529		
530		
531 532		
JJ2		

533	
534	
535	
536	
537	
538	
539 540	
541	
542	Figure Captions:
543	
544	Figure 1: Proportion of COVID-19 positive clients during Omicron period indicating
545	improvement, no change, or worsening of symptoms at time of test, among
546	symptomatic BinaxNOW positive participants testing within 14 days of symptom onset,
547	A. Overall, B. by Age Group and C. and by Vaccination Status
548	
549	Figure 2: BinaxNOW positivity among 942 repeat testers with COVID-19 during the
550	Omicron period by day of symptom onset (if symptomatic) or day since initial positive
551	test (if asymptomatic). COVID-19 status between a participant's tests is inferred to be
552	positive (if second test is positive) or with a linearly decaying probability of being
553	positive (if second test is negative). Panel A shows overall, including symptomatic and
554	asymptomatic people with dotted lines indicating upper and lower bounds of sensitivity
555	analysis. Sensitivity analysis assumes participants whose second test is negative either
556	immediately became negative after their first test (lower bound) or remained positive
557	until the day before their second test (upper bound). Panel B shows results stratified by

symptom status. Panel C show results stratified by self-report vaccination status as oftheir first test.

561	Supplementary Figure 1. Prevalence of selected symptoms among symptomatic
562	people testing positive and negative with the BinaxNOW rapid antigen test during pre-
563	Delta (January 10-May 31, 2021), Delta (June 1, 2021- November 30, 2021), and
564	Omicron period (December 1, 2021-January 30, 2021).
565	
566	Supplementary Figure 2: BinaxNOW positivity among 942 repeat testers with COVID-
567	19 during the Omicron period. by day of symptom onset (if symptomatic) or day since
568	initial positive test (if asymptomatic). A. Overall, includes symptomatic people and
569	asymptomatic people. B. Stratified by symptom status. Symptomatic include people who
570	report symptoms at the time of their initial positive test and who note a symptom onset
571	date and asymptomatic people include people who do not report symptoms at the time
572	of testing. C. Stratified by self-reported vaccination status.
573	
574	
575	
576	
577	
578	
579	
580	

581		
582		
583		
584		
585		
586		
587		

Table 1: Symptoms reported among symptomatic people testing positive and negative with the BinaxNOW rapid antigen test by, A. Variant period: Pre-Delta (January 10-May 31, 2021), Delta (June 1, 2021- November 30, 2021), Omicron Period.(December 1, 2021- January 30,20222)

	Overall (N=18,301)	Pre-Delta (N=5,533)		Delta (N=5,485)		Omicron (N=7,283)		Omicron vs. pre-Delta among positives	Omicron vs. Delta among positives
		Positive (n=1065)	Negative (n=4468)	Positive (n=468)	Negative (n=5017)	Positive (n=3032)	Negative (n=4251)	P-value (B-H corrected)	P-value (B-H corrected)
Symptoms									
Fever	3527 (19.3)	369 (34.7)	672 (15.0)	172 (36.8)	780 (15.6)	921 (30.4)	613 (14.4)	0.010 (0.02)	0.006 (0.015)
Cough	8885 (48.6)	546 (51.3)	1507 (33.7)	281 (60.0)	2356 (47.0)	2044 (67.4)	2151 (50.6)	<0.001 (0.003)	0.002 (0.006)
Shortness of breath	1386 (7.6)	93 (8.7)	409 (9.2)	42 (9.0)	346 (6.9)	241 (8.0)	255 (6.0)	0.42 (0.51)	0.45 (0.52)
Fatigue	3404 (18.6)	176 (16.5)	926 (20.7)	107 (22.9)	879 (17.5)	594 (19.6)	722 (17.0)	0.028 (0.051)	1 (1)
Myalgia	3896 (21.3)	322 (30.2)	978 (21.9)	141 (30.1)	829 (16.5)	868 (28.6)	758 (17.8)	0.32 (0.41)	0.51 (0.56)
Headache	6064 (33.1)	437 (41.0)	1693 (37.9)	167 (35.7)	1420 (28.3)	1075 (35.5)	1272 (29.9)	0.001 (0.003)	0.92 (0.96)
Loss of taste/smell	951 (5.2)	183 (17.2)	207 (4.6)	96 (20.5)	177 (3.5)	160 (5.3)	128 (3.0)	<0.001 (0.003)	<0.001 (0.003)
Sore throat	6570 (35.9)	315 (29.6)	1399 (31.3)	136 (29.1)	1821 (36.3)	1316 (43.4)	1583 (37.2)	<0.001 (0.003)	<0.001 (0.003)
Congestion	6217 (34.0)	294 (27.6)	1216 (27.2)	193 (41.2)	1866 (37.2)	1177 (38.8)	1471 (34.6)	<0.001 (0.003)	0.32 (0.41)
Nausea	1108 (6.1)	75 (7.0)	295 (6.6)	29 (6.2)	324 (6.5)	150 (5.0)	235 (5.5)	0.010 (0.020)	0.25 (0.37)
Diarrhea	1192 (6.5)	65 (6.1)	425 (9.5)	28 (6.0)	304 (6.1)	144 (4.8)	226 (5.3)	0.08 (0.135)	0.25 (0.37)

Abbreviations: B-H corrected= Benjamin-Hochberg method

Table 2: Symptoms reported among symptomatic people testing positive and negative with the BinaxNOW rapid antigen test during the Omicron period (December 1, 2021-January 30,20222), stratified by age group.

	Overall — (N=7,283)	Age ≥18 (N=5779)		Age 12-17 (N=664)		Age <12 (N=840)		Age <u>></u> 18 vs. 12-17 among positives	Age <u>></u> 18 vs. <12 Among positives
		Positive (n=2419)	Negative (n=3360)	Positive (n=311)	Negative (n=353	Positive (n=302)	Negative (n=538)	P-value (B-H corrected)	P-value (B-H corrected)
Symptoms									
Fever	1534 (21.1)	733 (30.3)	492 (14.6)	84 (27.0)	52 (14.7)	104 (34.4)	69 (12.8)	0.23 (0.46)	0.14 (0.31)
Cough	4195 (57.6)	1626 (67.2)	1617 (48.1)	218 (70.1)	186 (52.7)	200 (66.2)	348 (64.7)	0.31 (0.55)	0.73 (0.90)
Shortness of breath	496 (6.8)	209 (8.6)	221 (6.6)	22 (7.1)	25 (7.1)	10 (3.3)	9 (1.7)	0.35 (0.55)	0.001 (0.002)
Fatigue	1316 (18.1)	538 (22.2)	664 (19.8)	33 (10.6)	33 (9.4)	23 (7.6)	25 (4.7)	<0.001 (0.002)	<0.001 (0.002)
Myalgia	1626 (22.3)	779 (32.2)	681 (20.3)	63 (20.3)	51 (14.5)	26 (8.6)	26 (4.8)	<0.001 (0.002)	<0.001 (0.002)
Headache	2347 (32.2)	898 (37.1)	1118 (33.3)	124 (39.9)	99 (28.1)	53 (17.6)	55 (10.2)	0.35 (0.55)	<0.001 (0.002)
Loss of taste/smell	288 (4.0)	141 (5.8)	112 (3.3)	18 (5.8)	12 (3.4)	1 (0.3)	4 (0.7)	0.98 (0.98)	<0.001 (0.002)
Sore throat	2899 (39.8)	1099 (45.4)	1364 (40.6)	140 (45.0)	121 (34.3)	77 (25.5)	98 (18.2)	0.89 (0.93)	<0.001 (0.002)
Congestion	2648 (36.4)	960 (39.7)	1156 (34.4)	126 (40.5)	111 (31.4)	91 (30.1)	204 (37.9)	0.78 (0.90)	0.001 (0.002)
Nausea	385 (5.3)	118 (4.9)	182 (5.4)	16 (5.1)	21 (6.0)	16 (5.3)	32 (6.0)	0.84 (0.92)	0.75 (0.90)
Diarrhea	370 (5.1)	119 (4.9)	71 (5.1)	12 (3.9)	38 (10.8)	13 (4.3)	17 (3.2)	0.41 (0.60)	0.64 (0.88)

Abbreviations: B-H corrected= Benjamin-Hochberg method

Table 3: Symptoms reported among symptomatic people testing positive and negative with the BinaxNOW rapid antigen test during the Omicron period (December 1, 2021-January 30,20222), stratified by vaccination status.

	Overall (N=5424)	Unvaccinated (N=233)		Vaccinated, not boosted (N=3817)		Vaccinated, Boosted (N=1374)		Boosted vs. Unvaccinated among positives	Boosted vs. Vaccinated, not boosted among positives
		Positive (n=116)	Negative (n=117)	Positive (n=1705)	Negative (n=2112)	Positive (n=432)	Negative (n=942)	P-value (B-H corrected)	P-value (B-H corrected)
Symptoms									
Fever	1162 (21.4)	42 (36.2)	16 (13.7)	559 (32.8)	343 (16.2)	97 (22.5)	105 (11.2)	0.003 (0.01)	<0.001 (0.01)
Cough	3060 (56.4)	71 (61.2)	53 (45.3)	1191 (69.9)	1086 (51.4)	268 (62.0)	391 (41.5)	0.87 (1)	0.002 (0.01)
Shortness of breath	408 (7.5)	10 (8.6)	7 (6.0)	150 (8.8)	150 (7.1)	36 (8.3)	55 (4.8)	0.92 (1)	0.76 (0.93)
Fatigue	1144 (21.1)	33 (28.5)	25 (21.4)	372 (21.8)	410 (19.4)	104 (24.1)	200 (21.2)	0.33 (0.50)	0.31 (0.50)
Myalgia	1383 (25.5)	41 (35.3)	25 (21.4)	580 (34.0)	440 (20.8)	115 (26.6)	182 (19.3)	0.06 (0.19)	0.003 (0.01)
Headache	1921 (35.4)	49 (42.2)	42 (35.9)	646 (37.9)	719 (34.0)	153 (35.4)	312 (33.1)	0.18 (0.40)	0.34 (0.50)
Loss of taste/smell	240 (4.4)	12 (10.3)	7 (6.0)	99 (5.8)	76 (3.6)	25 (5.8)	21 (2.2)	0.08 (0.22)	0.99 (1)
Sore throat	2325 (42.9)	48 (41.4)	34 (29.1)	776 (45.5)	850 (40.3)	208 (48.2)	409 (43.4)	0.20 (0.40)	0.33 (0.50)
Congestion	2019 (37.2)	40 (34.5)	32 (27.4)	668 (39.2)	701 (33.2)	207 (47.9)	371 (39.4)	0.010 (0.04)	0.001 (0.01)
Nausea	290 (5.4)	7 (6.0)	6 (5.1)	89 (5.2)	119 (5.6)	18 (4.2)	51 (5.4)	0.39 (0.50)	0.37 (0.50)
Diarrhea	277 (5.1)	10 (8.6)	2 (1.7)	83 (4.9)	112 (5.3)	21 (4.9)	49 (5.2)	0.12 (0.29)	1 (1)

Abbreviations: B-H corrected= Benjamin-Hochberg method

	Overall	Pre-Delta	Delta	Omicron	P-value
	(N=18,301)	(N=5,533)	(N=5,485)	(N=7,283)	
Age Category (years)					
<5	684 (3.7)	113 (2.0)	285 (5.2)	286 (3.9)	<0.001
5-11.9	1510 (8.3)	169 (3.1)	787 (14.4)	554 (7.6)	
12-17.9	1343 (7.3)	274 (5.0)	405 (7.4)	664 (9.1)	
18-30	4985 (27.2)	1725 (31.2)	1385 (25.3)	1875 (25.7)	
31-50	7020 (38.4)	2323 (42.0)	1909 (34.8)	2788 (28.3)	
51-64	2215 (12.1)	735 (13.3)	570 (10.4)	910 (12.5)	
65 and older	544 (3.0)	194 (3.5)	144 (2.6)	206 (2.8)	
Gender ^a					
Male	8513 (46.9)	2643 (47.8)	2517 (46.4)	3353 (46.5)	<0.001
Female	9394 (51.7)	2761 (49.9)	2830 (52.2)	3803 (52.7)	
Non-binary	234 (1.3)	106 (1.9)	73 (1.4)	55 (0.8)	
Prefer not to say	27 (0.2)	23 (0.4)	4 (0.1)	0	
Ethnicity					
Asian	1032 (6.1)	269 (6.1)	402 (7.5)	361 (5.0)	<0.001
Black/African American	256 (2.1)	145 (3.3)	112 (2.1)	99 (1.4)	
Latinx/Hispanic	11856 (69.7)	3120 (70.2)	3408 (63.3)	5328 (74.3)	
White/Caucasian	2157 (12.7)	618 (13.9)	926 (17.2)	613 (8.5)	
Other	1606 (9.5)	295 (6.6)	536 (10.0)	775 (10.8)	
Vaccine Status ^c					<0.001
Not Vaccinated	874 (16.2)	167 (93.3)	67 (39.7)	640 (12.7)	
Partially Vaccinated	1248 (23.1)	9 (5.0)	51 (30.2)	1188 (23.5)	
Primary Vaccine Series	2032 (37.6)	3 (1.7)	46 (27.2)	1983 (39.2)	
Primary Vaccine Series with Booster	1249 (24.8)	^d	5 (3.0)	1244 (24.6)	
Vaccine Status (over 18 years) ^e					<0.001
Not Vaccinated	388 (9.3)	137 (92.6)	40 (29.2)	211 (5.4)	
Partially Vaccinated	964 (23.0)	8 (6.1)	48 (35.0)	908 (23.3)	
Primary Vaccine Series	1618 (38.6)	3 (2.0)	44 (32.1)	1571 (40.2)	
Primary Vaccine Series with Booster	1220 (29.1)	d	5 (3.6)	1215 (31.1)	

Supplementary Table 1: Demographics of symptomatic people seeking testing from January 2020-January 2021, by variant-period.

^a133 missing responses ^b1294 missing responses ^c2899 missing responses ^dBooster shots were not available at any point during this period ^e1657 missing responses

Supplementary Table 2. Proportion symptomatic participants reporting only one of the following symptoms the time of testing during the Omicron period ((December 1, 2021-January 30, 2021)

Symptom Type	Overall (N=3032)	Age ≥18 (N=2419)	Age 12-17 (N=311)	Age <12 (N=302)	P-value
Fever	74 (2.4)	45 (1.9)	3 (1.0)	26 (8.6)	<0.001
Cough	477 (15.7)	346 (14.3)	48 (15.4)	83 (27.5)	0.030
Shortness of breath	4 (0.1)	4 (0.2)	0	0	1
Fatigue	12 (0.4)	10 (0.4)	0	2 (0.7)	0.41
Myalgia	25 (0.8)	22 (0.9	2 (0.6)	1 (0.3)	0.76
Headache	51 (1.7)	37 (1.5)	11 (3.5)	3 (1.0)	0.036
Loss of taste/smell	5 (0.2)	4 (0.2)	1 (0.3)	0	0.68
Sore throat	168 (5.5)	147 (6.1)	17 (5.5)	4 (1.3)	0.001
Congestion	140 (4.6)	100 (4.1)	17 (5.5)	23 (7.6)	0.019
Nausea	4 (0.1)	3 (0.1)	0	1 (0.3)	0.39
Diarrhea	2 (0.1)	1 (0.0)	0	1 (0.3)	0.20
Any of the above symptoms in isolation	962 (31.7)	719 (29.7)	99 (31.8)	144 (47.7)	<0.001

Figure 1: Proportion of COVID-19 positive clients during Omicron period indicating improvement, no change, or worsening of symptoms at time of test, among symptomatic BinaxNOW positive participants testing within 14 days of symptom onset, A. Overall, B. by Age Group and C. and by Vaccination Status




Figure 2: BinaxNOW positivity among 942 repeat testers with COVID-19 during the Omicron period by day of symptom onset (if symptomatic) or day since initial positive test (if asymptomatic). COVID-19 status between a participant's tests is inferred to be positive (if second test is positive) or with a linearly decaying probability of being positive (if second test is negative). Panel A shows overall, including symptomatic and asymptomatic people with dotted lines indicating upper and lower bounds of sensitivity analysis. Sensitivity analysis assumes participants whose second test is negative either immediately became negative after their first test (lower bound) or remained positive until the day before their second test (upper bound). Panel B shows results stratified by symptom status. Panel C show results stratified by self-report vaccination status as of their first test.

